San Francisco, California, USA | March 20, 2026
Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin, a first-in-class regulatory T-cell (Treg) stimulator, has been accepted for two oral presentations at the American Academy of Dermatology (AAD) 2026 Annual Meeting, highlighting significant progress in the treatment of autoimmune and inflammatory skin diseases. The data spans studies in atopic dermatitis and alopecia areata, reinforcing the drug’s potential to address underlying immune dysregulation rather than just symptoms, marking an important milestone in clinical-stage immunotherapy development.
Phase 2b Clinical Studies Demonstrate Efficacy and Safety
The Phase 2b program includes two major studies—REZOLVE-AD in atopic dermatitis and REZOLVE-AA in alopecia areata—both designed to evaluate efficacy, safety, and dose-response relationships of rezpegaldesleukin. In the alopecia areata trial, patients with severe-to-very-severe disease were randomized across dosing regimens, with the primary endpoint measuring reduction in SALT (Severity of Alopecia Tool) scores at 36 weeks, a key clinical indicator of hair regrowth and disease improvement.
Similarly, the atopic dermatitis study enrolled 393 patients globally, assessing outcomes such as EASI (Eczema Area and Severity Index) score reductions and long-term maintenance responses, demonstrating the drug’s ability to achieve clinically meaningful improvements in moderate-to-severe disease. These studies were conducted across multiple international clinical sites, ensuring robust and diverse patient representation, which strengthens the generalizability of the findings.
Novel Mechanism Targets Immune System Imbalance
Advertisement
Rezpegaldesleukin represents a novel therapeutic approach by selectively targeting the interleukin-2 (IL-2) receptor pathway to stimulate regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance and preventing autoimmune responses. Unlike conventional therapies that suppress the immune system broadly, this drug is designed to restore immune balance by enhancing regulatory pathways without activating pro-inflammatory T cells, offering a more precise and potentially safer treatment strategy.
This mechanism is particularly relevant in conditions such as atopic dermatitis and alopecia areata, where immune system dysregulation leads to chronic inflammation and tissue damage. By addressing the root cause of disease, rezpegaldesleukin has the potential to deliver durable therapeutic benefits and improved long-term disease control.
Regulatory Progress and Clinical Development Outlook
The advancement of rezpegaldesleukin is further supported by its Fast Track designation from the U.S. FDA for both moderate-to-severe atopic dermatitis and severe alopecia areata, underscoring its potential to address significant unmet medical needs.
The acceptance of Phase 2b data for oral presentations at a major scientific congress like AAD 2026 reflects the clinical significance and scientific rigor of the findings, as oral presentations are typically reserved for high-impact studies with meaningful clinical outcomes. This milestone positions rezpegaldesleukin for potential advancement into late-stage (Phase 3) development, which could ultimately support regulatory submissions and commercialization.
Furthermore, the drug is being developed as a self-administered subcutaneous therapy, which could enhance patient convenience, adherence, and real-world usability, key considerations in chronic disease management and Good Clinical Practice (GCP) frameworks.
The Phase 2b data for rezpegaldesleukin highlights a promising advancement in immunology-driven therapeutics, demonstrating clinical efficacy, safety, and a novel mechanism of action in treating autoimmune dermatological conditions. With strong clinical trial design, regulatory support, and growing scientific validation, the therapy represents a next-generation approach to restoring immune balance, potentially transforming treatment paradigms in chronic inflammatory diseases.
Source: Nektar Therapeutics press release
